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Rationale, aims and objectives 
Use of continuous subcutaneous insulin infusion therapy in type 1 diabetes management is 
high. However, the incorporation of this technology into self-care is not without challenges, 
and the support of an appropriately skilled healthcare team is recommended. This study 
aimed to examine the support context for patients using continuous subcutaneous insulin 
infusion therapy from the healthcare professional perspective, as well as contextual 
influences for healthcare professionals and their patients. 
Methods 
This ethnographic qualitative study was undertaken in New South Wales, Australia. 
Recruitment occurred using a snowball sampling technique, beginning with members of an 
established diabetes service group. Data were collected through the use of semi-structured 
interviews undertaken by telephone and analysed using thematic analysis. 
Results 
Data were obtained from 26 interviews with staff from diverse professional backgrounds. An 
overarching theme of difficulties, disconnections and disarray emerged, with findings 
indicating that participants perceived difficulties in relation to shortages of healthcare 
professional continuous subcutaneous insulin infusion-related expertise, and disconnected 
and disarrayed service structures and process, with barriers to access to these devices. 
Individual healthcare professionals were left to manage somehow or opted not to engage with 
related care. 
Conclusions 
Findings provide insights from healthcare professionals’ perspectives into the complexity of 
providing support for patients using continuous subcutaneous insulin infusion therapy across 
diverse contexts, and provide a platform for further research and service development. The 
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need for consistent and coordinated care, and the infrastructure to facilitate this, flags an 




Good glycaemic control is recognised as essential for the prevention or deferral of 
complications in type 1 diabetes (T1D) [1]. Continuous subcutaneous insulin infusion (CSII; 
insulin pump) therapy, as a method of insulin delivery, has been shown to facilitate such 
control for some and has been linked to improved quality of life [2-4]. Consequently, in many 
countries CSII uptake has been high. In the United States, for example, up to one in two 
people with T1D are using this technology [5, 6]. Uptake is lower in other countries, at 
around one in ten in Germany, Sweden and Australia, but increasing rapidly [7, 8]. In 
Australia, most recent data indicate that CSII usage as a method of insulin delivery 
consistently increased by an average of 107 to 140 new users each month from 2004-2010 
[7], with the majority (70%) of users situated in major cities [7, 9]. In Australia it is younger 
people with type 1 diabetes who predominantly choose CSII technology, with approximately 
one in every two CSII users under the age of 25 years [7]. 
 
In the groups in which CSII is likely to be beneficial, usage is affected by many factors. For 
instance, uptake can be influenced by the capacity of the individual to pay for the device and 
the provision of expert staff. Therefore, funding policies and related processes are important, 
and vary across countries. A CSII device may be provided for patients with type 1 diabetes, 
irrespective of financial circumstance in Ontario, Canada, for example [10, 11], whilst in 
Australia the government provides limited means tested funding for low income families with 
children with type 1 diabetes [12]. CSII devices in Australia may also be obtained through 
personal finance, clinical trial enrolment, charitable donations or private health insurance, 
which often entails a lengthy application process and hospital admission at the time of CSII 
commencement. The majority (88%) of CSII users in Australia receive financial assistance to 
acquire their device, with almost all (97%) using private health insurance [7]. The 
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consequence of this method of purchase is that usage is more commonplace in higher socio-
economic areas (14% versus 6%) [43]. Regardless of age, the consumables needed for 
patients with type 1 diabetes to use CSII technology are subsidised by the Australian 
Government, subject to eligibility criteria, as part of the National Diabetes Services Scheme 
[13]. 
 
CSII use almost always necessitates support from an appropriately skilled multi-disciplinary 
healthcare professional (HCP) team [7, 14-17], to determine insulin dosage algorithms, 
provide education and strategies to manage risks and achieve the anticipated benefits of CSII 
therapy [18, 19]. However, many Australian healthcare services are facing difficulty in 
meeting the increasing service support demand for CSII use [20]. Despite these well-known 
service and staffing concerns, there is little information about how patients using CSII 
therapy are supported from the perspective of responsible HCPs. This information is needed 
for comprehensive service planning and quality assessment processes, particularly for those 
living outside metropolitan areas and young people. This study aimed to examine from the 
HCP perspective the support context for patients using CSII therapy, as well as contextual 
influences for HCPs and their patients. 
 
METHODS 
This qualitative study was undertaken using an ethnographic research design in partnership 
with Hunter New England Local Health District (HNELHD), a regional public health 
services provider in New South Wales (NSW), Australia. HNELHD provides services for 
approximately 850,000 residents across 130,000 square kilometres of NSW [21], including 
metropolitan, regional and rural areas. Participants were eligible for the study if they were 
HCPs with current or recent responsibility for providing care for people with T1D using CSII 
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therapy. Ethical approval was obtained from HNELHD and University of Newcastle Human 
Research Ethics Committees. 
 
Recruitment occurred using a snowball sampling technique, as there was no list of eligible 
diabetes HCPs in HNELHD. Sampling began with members of an established HNELHD-
wide diabetes service group. All contacts were asked to voluntarily identify HCPs they were 
aware of with current or previous experience with CSII therapy, regardless of whether they 
themselves decided to participate or not. The process was repeated until there was broad 
representation across HCP groups and geographical locations, and it was felt data saturation 
had been achieved. At first contact potential participants were supplied with a letter of 
introduction, study information and a consent form. 
 
Data were collected using individual semi-structured interviews undertaken by an 
experienced female clinical researcher (a Registered Nurse and Credentialed Diabetes 
Educator) by telephone during 2011-2012. Telephone interviews were chosen to facilitate 
participation by rural and regional HCPs and provide privacy for sharing potentially sensitive 
information or opinions. The interview schedule (Appendix 1) was developed during 
discussion by research team members, reviewed by clinicians from another health district, 
piloted and provided to consenting participants ahead of the telephone interviews. 
Participants were also asked to briefly describe their geographical location, professional 
background and, depending upon their employment, either their personal or service caseload 
of CSII users. Each interview commenced with an introduction and explanation of 
confidentiality principles. All interviews were audio recorded and brief field notes collected. 
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Audio data and interview field notes were transcribed and imported into NVivo 10 software. 
All data were de-identified. Data analysis was guided by Gibb’s [22] framework and 
organised thematically. The framework included transcription and familiarisation, code 
building, theme development, data consolidation and interpretation. Transcripts were read by 
three authors (SJ, RG and LP) with coding initiated by one author (SJ). This was followed by 
emergent coding and organisation of themes, developed during discussion with all authors to 
reach consensus. Multiple investigators for the analysis allowed development of 
complementary and divergent understandings, and provided a context in which beliefs, 
values, perspectives and assumptions could be revealed and contested. Transcripts were not 





Twenty-seven semi-structured telephone interviews were conducted with a variety of HCPs 
working at diverse sites across metropolitan (n=15), regional and rural areas (n=12); one non-
metropolitan interview was inaudible. Interviews analysed lasted mean (SD) 30 (14.4) 
minutes and participants identified themselves as diabetes nurse educators (n=12, one also a 
health service manager), dietitians (n=3), endocrinologists (n=5, 3 paediatric and 2 adult), 
paediatricians (n=3), and general practitioners (n=3). The paediatric CSII caseloads of HCPs 
ranged from one to one-hundred and fifty; those of adult HCPs ranged from two to sixty-five 
patients. 
 
An overarching theme of difficulties, disconnections and disarray emerged from the data. 
Difficulties occurred partly as a result of the availability and range of appropriate CSII 
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expertise, which was perceived to exert a pervasive effect. This was in addition to barriers to 
access to CSII devices, consequent to government and private health insurance policy 
conditions. A lack of shared access to documentation and communication between adult and 
paediatric services, between separate components of the health service and with HCPs across 
organisations, resulted in disconnections which hindered a consistent, coordinated and 
informed approach to care. Finally, disarray followed the absence of consensus or definition 
for some key organisational processes and the subsequent delivery of care that was 
sometimes not standardised or consistent. There was also no consensus or policy for the 
specific training processes required by HCPs to provide CSII-related care. 
 
Shortages of HCP expertise 
Participants (particularly those working in non-metropolitan locations) expressed frustration 
with the lack of specific HCP expertise available for their patients, which they considered 
essential to support CSII use: 
 
“Because we have no endocrinologist up here…. in effect there is really no service for 
young adults here on insulin pump therapy.” (HCP 26: non-metropolitan) 
 
However, there was no consensus or policy for the specific training processes required by 
HCPs to provide CSII-related care. Competence was often obtained serendipitously and in 
many cases was funded by the individuals themselves or provided by diverse CSII 
manufacturers. This unsystematic approach to education may have contributed to the 
inconsistent support for CSII use. The availability and range of appropriate CSII expertise 
was perceived to exert a pervasive effect, including determination of whether CSII use was 
initiated or even raised as an option with a patient. Even more problematic, some health 
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providers were reported as declining to engage in discussion or management of diabetes with 
current CSII users. As one paediatric endocrinologist stated: 
 
“The system doesn’t allow for initiating or monitoring children or adolescents, or young 
adults on pumps here anyway.” (HCP 12: non-metropolitan) 
 
This apparent failure of the system to acknowledge and engage with this care need occurred 
across the continuum of care, including while the patient was admitted to hospital, unwell and 
in need of support. This was most commonly reported in non-metropolitan areas.  
 
The consequences of the lack of CSII expertise were far-reaching: those experts that were 
available had limited time, so extra efforts had to be made by non-expert staff to maximise 
the experts’ time to address patients’ issues. This could occur in metropolitan areas as well, 
as explained by a diabetes nurse educator: 
 
“It’s a real effort trying to contact support doctors because we don’t have any on site. The 
only time we have people on site is for the…. clinic so if I’ve got any issues that are 
burning I’ll confront them…. at the clinic.” (HCP 04: metropolitan) 
 
The lack of expertise in hospital settings also meant that expert staff (predominantly the 
diabetes nurse educators) reported commonly going above and beyond their work 
requirements by providing personal telephone numbers to patients and their immediate 
families. However, the processes applied in identifying who required this extra support and 
for whom the HCPs were willing to disrupt their home life were unclear, but it was obvious 
that some degree of personal risk was perceived by participants: 
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“It sort of sounds bad but it depends on the client…. I always give my home number and 
my mobile number if they need it, but I might be a bit careful with some people about 
giving that out if I think that it’s going to backfire on me.” (HCP 16: non-metropolitan) 
 
Despite this, few of the more expert participants expressed concern about their colleagues’ 
difficulties. Only one interviewee (a diabetes nurse educator) raised other HCPs’ needs or 
expressed a sense of responsibility to support those in non-metropolitan settings: 
 
“I think we should have maybe a few meetings where the issues with insulin pump 
therapy…. what the guys out in the country need.” (HCP 20: metropolitan) 
 
Service structure and process shortfalls 
The lack of shared access to documentation and communication between adult and paediatric 
services, between separate components of the health service and with HCPs across 
organisations hindered a coordinated approach to care. Where patients had been lost to 
follow-up, participants (predominantly physicians) reported being unaware whether patients 
had connected with a diabetes service in another location. The assessments and plans 
activated by one professional could be largely unknown to another, resulting in patients 
repeating their history and providers duplicating efforts. One general practitioner emphasised 
his frustration at not having reciprocal access to the records of the local hospital, children’s 
hospital or community health: 
 
“They [healthcare records] all seem to be in three separate places, so they [HCPs] all have 
to take another full history and go through it all.” (HCP 27: non-metropolitan) 
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Lack of access to records meant that specialists could be asked to make recommendations 
based on very little information. For example, this endocrinologist expressed discomfort at 
signing approvals to commence CSII therapy: 
 
“A lot of patients come into clinic as a one off…. use me as a one off specialist to sign 
them off for the pump, which I’m not really happy about. They [the patients] have never 
seen me before…. I don’t know what level of knowledge and skills they have.” (HCP 21: 
metropolitan) 
 
Another deficit was the absence of consensus or definition for some key organisational 
processes. Subsequently, care provided was not standardised with potential for advice to CSII 
users to vary for initiation, maintenance and support of this technology when considering 
aspects such as patient selection, expertise provided and follow-up, depending on the location 
and individual HCPs they attended. ‘Hit and miss’ processes potentially resulted in 
inconsistent patient follow-up: 
 
“At the moment there’s no recognised program in place. It’s all hit and miss .... There’s a 
real risk, in the current setup, that we put people on pumps, we see them perhaps a couple 
of times afterwards and then they sort of disappear into the wilderness.” (HCP 29: 
metropolitan) 
 
CSII device access 
The ability of patients to commence CSII therapy or update their CSII device was ultimately 
influenced by access to funding. Individuals who did not have private health insurance or 
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personal resources often could not afford initial set-up costs. Some CSII users had the device 
provided in childhood through a government subsidy but had difficulties as they transitioned 
from childhood because the subsidy ceased and, starting their working lives, their financial 
circumstances prohibited purchase. This sometimes meant low income young adults 
continuing to use their CSII device beyond the life and optimal function of the equipment. 
Participants had no option but to continue providing support in this situation, even if it was 
not what they saw as the patient’s best interest: 
 
“The pump itself is faulty because it’s very old and at the moment she [the patient] doesn’t 
have the resources to acquire another pump.” (HCP 26: non-metropolitan). 
 
Private health insurance providers’ requirements for funding CSII devices influenced service 
delivery. All private health insurance funds required a physician specialising in diabetes to 
sign an approval to commence CSII therapy; many also required a hospital admission at the 
time of commencement. Many participants (particularly rural staff) viewed this requirement 
as useful both socially and economically because of the distances some patients would have 
to travel, in the event of technical, operational or related medical problems. Others 
(particularly metropolitan staff), however, saw this in a more negative light, considering the 
disruption to patients’ lives and costs to the public healthcare system irrespective of clinical 
need. Some participants navigated around this requirement by creating virtual wards so 
patients were not physically admitted, thereby reducing the impact of an admission on their 
patients and the wider public health system. 
 
Collectively, from HCPs’ perspectives, issues illustrated difficulties, disconnections and 
disarray in the support for patients using CSII, and how this context functions for HCPs and 
16 
their patients. Inequities and uncoordinated healthcare were described. This reflected lack of 
specific expertise in some locations but also lack of teamwork and common agreed care 
policies and processes, all undermined by lack of common data systems, communication 
infrastructure and connectivity. This left unsupported individuals unwilling to contribute to 
CSII care, and forced others to decide for themselves which patients received what forms of 
support. 
 
HCPs perceived benefits and shortfalls accruing to government and private health insurance 
policy conditions. Government policy recognised the importance of supporting equity of 
access for disadvantaged children. However, eligibility for the CSII device subsidy ceased at 
age 18 years, whereas the economic disadvantage could persist beyond this. Private health 
insurers requiring a hospital admission for CSII commencement irrespective of clinical need 
potentially benefited some patients but unnecessarily burdened others and the public 




This study provides insights into HCPs’ perspectives of the complexity of providing support 
for patients using CSII therapy across diverse contexts, and lays out a platform for further 
research and service innovation. Previous local and international research focusing on service 
support for T1D, and chronic disease in general, have also demonstrated deficiencies in 
planning and provision of specialist HCP expertise and management [23-26]. This group of 




CSII users need ongoing support and monitoring, and their healthcare teams need to be able 
to deliver this, to provide the best chance to delay or deter the development of vascular 
complications that are seen in people with T1D at young ages [27, 28], and their associated 
costs [29]. Economic analysis under research conditions has demonstrated the benefit of CSII 
versus multiple daily injections [30]. What is needed now is to put into daily clinical practice 
those elements that are required to translate the benefits seen in research into ‘business as 
usual’ clinical practice. The findings of this study flag important deficits that may need 
attention, in order for this to occur. 
 
Ways to promote and support engagement, both for patients and HCPs, should be considered 
[20]. Eligibility criteria for a CSII device subsidy from the Australian Government includes 
the stated presence of a system to ensure follow-up and ongoing support [12]. However, there 
are no in-built facilitators, inducements or monitoring to ensure that this is honored. Further, 
outside of National Diabetes Services Scheme registration requirements there are no in-built 
facilitators or inducements to promote regular engagement of CSII users with diabetes health-
care teams; in this study the risk of patients being lost to CSII-related follow-up was 
highlighted. This flags, at minimum, the need for integration of healthcare records on a 
mandatory rather than voluntary basis, with pan-Australian access accorded to healthcare 
providers across primary to tertiary services. Financial incentives to maintain contact with 
health services such as those in Ontario, Canada, could also be considered [31]. 
 
Many staff (predominantly in metropolitan areas) expressed the need for improved and 
perhaps dedicated services for CSII users. This strategy could support development of a 
structured team approach, potentially enabling more consistent patient follow-up and perhaps 
better patient outcomes from CSII usage. A place to start might be in the dissemination and 
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adoption of Australian evidence-based CSII therapy clinical guidelines [15]. Policies and 
procedures to translate guidelines into practice should be formulated. These should consider 
the appropriate selection of patients for CSII use and self-management, as well as the 
expertise required by HCPs to care for CSII users and support other staff [14-16]; to enable 
professional development of competent HCPs to support CSII related care. Australian state-
based guidelines for in-hospital CSII care are available [32]. 
 
To augment the dedicated services suggested above, phone, online and electronic support can 
be considered, particularly for young people [24] and staff in rural areas. Technologies such 
as video-conferencing may also benefit and facilitate the provision of peer support amongst 
diabetes HCPs, and HCP support for patients where this is otherwise locally lacking [33]. 
Whether CSII is the best option for a patient needs to be carefully considered, including at the 
time of transition, also taking account of ongoing access to appropriate supportive care. 
 
Findings also suggest that policy innovation may also be required to enable equitable CSII 
access. Australian government funding for access to a CSII device, supportive of children, 
could potentially be extended to cover the early adult years of eligible young people with 
T1D [20]. Aspects such as device and consumable provision, upgrades and the technology 
support required to achieve the anticipated benefits for the entire period of CSII therapy use 
should be further investigated. Given the complex nature of patterns of socio-economic 
advantage and disadvantage amongst the community, it is possible that increased financial 
support alone might exacerbate rather than ameliorate inequalities between those who can 
afford to use CSII and those who cannot. 
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The representative nature of the sample from which findings derived is impossible to gauge. 
Nonetheless the sample comprised a large proportion of healthcare providers covering a very 
large geographical area. The use of snowball sampling may have generated sampling bias due 
to initial participants nominating HCPs they knew, who may have shared opinions as well as 
experiences, and whose recruitment was by self-selection. These HCPs were employed by a 
single public healthcare provider, albeit participants worked as members of multiple different 
local teams. Findings reflect their experiences and perceptions at one point in time. 
 
In summary, findings clearly indicate the need for policy and practice innovation to better 
enable staff to support patients with T1D using CSII therapy, and to support staff providing 
this care, especially in non-metropolitan areas. The need for consistent and coordinated care, 
and the infrastructure to facilitate this, drives an opportunity to reconfigure relationships 
between acute centres (often the repositories of specialist expertise) and community/primary 
care, where such expertise is required for preventive care but often lacking. It presents an 
opportunity to drive integration of care, and team-working, across as well as within 
disciplines and settings. 
 
Comprehensive service planning and monitoring involving diabetes HCPs nationwide may be 
required; in many geographical areas appropriate resource allocation and use of other 
technologies to promote engagement with and between diabetes services may be warranted to 
demonstrate the comparative cost effectiveness of service redesign. Diabetes technology is 
advancing rapidly, requiring a skilled and responsive workforce and flexible health services 
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Appendix 1 – Semi-structured interview schedule 
 
Thinking about the young people with type 1 diabetes on your caseload who use an insulin 
pump, now or in the recent past: 
 
1. Have any of your patients ever used an insulin pump? How many would you have, 
and can you tell me a little about them, including where they were started on their 
pump or who initiated their insulin pump treatment? 
2. What is your role in their ongoing care? For example, are you actively involved in 
supporting and monitoring their pump use? If so, please describe. 
3. Within your area, how many healthcare professionals are actively involved with 
initiating, monitoring and supporting young people with insulin pumps? What are 
their roles? 
4. Are there sufficient services and knowledgeable health care professionals available to 
treat young adults with pumps in your area? 
If not, which areas are well serviced and which could be strengthened? 
5. Have there been any recent changes to improve services in your area? If so, please 
describe them. 
What sort of differences are they making? (to service provision and to the cost of 
service provision) 
6. What are the enablers and barriers to interactions with other service providers (GPs, 
physicians, hospital staff, private providers like dietitians, podiatrists, optometrists, 
ophthalmologists, and pathology) in better managing young people using insulin 
pumps? 
Can you suggest anything that might improve this? 
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7. What are your thoughts about the adequacy of current service models and processes 
for initiation, maintenance and support of young people on insulin pumps to meet 
future demand in your diabetes service? 
8. Is there anything else you would like to add? 
 
